Imunon (CBO0) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Paclitaxel, Carboplatin, Olaparib, Niraparib, Imnn-001 (Il-12 Plasmid Formulated With Peg-Pei-Cholesterol Lipopolymer) | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Ovarian Cancer | Phase III | Recruiting | Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer | Apr 01, 2025 | ― |
| Imnn-101 | Sars Cov 2 Infection | phase1AndPhase2 | Completed | Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2 | Feb 22, 2024 | ― |
| Bevacizumab, Paclitaxel, Carboplatin, Imnn-001 | Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer | phase1AndPhase2 | Recruiting | Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Feb 13, 2023 | ― |
| Paclitaxel, Carboplatin, Imnn-001 | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | phase1AndPhase2 | Active Not Recruiting | Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) | Jan 03, 2018 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Paclitaxel, Carboplatin, Olaparib, Niraparib, Imnn-001 (Il-12 Plasmid Formulated With Peg-Pei-Cholesterol Lipopolymer) | Phase III | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Ovarian Cancer | Recruiting | Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer | Apr 01, 2025 | ― |
| Imnn-101 | phase1AndPhase2 | Sars Cov 2 Infection | Completed | Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2 | Feb 22, 2024 | ― |
| Bevacizumab, Paclitaxel, Carboplatin, Imnn-001 | phase1AndPhase2 | Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer | Recruiting | Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Feb 13, 2023 | ― |
| Paclitaxel, Carboplatin, Imnn-001 | phase1AndPhase2 | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | Active Not Recruiting | Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) | Jan 03, 2018 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Imunon, Inc. (DE:CBO0) have in its pipeline
Imunon DE:CBO0 is currently developing the following drugs: Paclitaxel, Carboplatin, Olaparib, Niraparib, Imnn-001 (Il-12 Plasmid Formulated With Peg-Pei-Cholesterol Lipopolymer), Imnn-101, Bevacizumab, Paclitaxel, Carboplatin, Imnn-001, Paclitaxel, Carboplatin, Imnn-001. These drug candidates are in various stages of clinical development as the company works toward FDA approval.